Literature DB >> 23715780

Overexpression of response gene to complement 32 (RGC32) promotes cell invasion and induces epithelial-mesenchymal transition in lung cancer cells via the NF-κB signaling pathway.

Qinying Sun1, Xiaopeng Yao, Yunye Ning, Wei Zhang, Guowu Zhou, Yuchao Dong.   

Abstract

Response gene to complement 32 (RGC32) is a novel cellular protein that has been reported to be expressed aberrantly in multiple types of human tumors. However, the role of RGC32 in cancer is still controversial, and the molecular mechanisms by which RGC32 contributes to the development of cancer remain largely unknown. In the present study, we constructed a recombinant expression vector pCDNA3.1-RGC32 and transfected it into human lung cancer A549 cells. Stable transformanted cells were identified by real-time PCR and Western blot analysis. Functional analysis showed that forced overexpression of RGC32 increased invasive and migration capacities of lung cancer cells in vitro, and induced the acquisition of epithelial-mesenchymal transition (EMT) phenotype, as demonstrated by the spindle-like morphology, downregulation of E-cadherin, and upregulation of Vimentin, Fibronectin, Snail and Slug. Also, overexpression of RGC32 increased expression and activities of matrix metalloproteinase (MMP)-2 and MMP-9 in A549 cells. Furthermore, the downregulation of E-cadherin induced by RGC32 was remarkably attenuated by nuclear factor-κB (NF-κB) inhibitor BAY 11-7028 and small interfering RNA targeting NF-κB p65, suggesting a role of the NF-κB signaling pathway in RGC32-induced EMT. Taken together, our data suggest that RGC32 promotes cell migration and invasion and induces EMT in lung cancer cells via the NF-κB signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23715780     DOI: 10.1007/s13277-013-0864-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  21 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Cancer metastasis: building a framework.

Authors:  Gaorav P Gupta; Joan Massagué
Journal:  Cell       Date:  2006-11-17       Impact factor: 41.582

Review 3.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

4.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

Authors:  Farin Kamangar; Graça M Dores; William F Anderson
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

5.  RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase.

Authors:  Tudor Badea; Florin Niculescu; Lucian Soane; Matthew Fosbrink; Hila Sorana; Violeta Rus; Moon L Shin; Horea Rus
Journal:  J Biol Chem       Date:  2001-10-30       Impact factor: 5.157

6.  Response gene to complement 32 interacts with Smad3 to promote epithelial-mesenchymal transition of human renal tubular cells.

Authors:  Xia Guo; Pedro A Jose; Shi-You Chen
Journal:  Am J Physiol Cell Physiol       Date:  2011-02-09       Impact factor: 4.249

Review 7.  Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases.

Authors:  Beate Heissig; Koichi Hattori; Matthias Friedrich; Shahin Rafii; Zena Werb
Journal:  Curr Opin Hematol       Date:  2003-03       Impact factor: 3.284

Review 8.  Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.

Authors:  Susanna V Ulahannan; Julie R Brahmer
Journal:  Cancer Invest       Date:  2011-05       Impact factor: 2.176

Review 9.  The epithelial-mesenchymal transition: new insights in signaling, development, and disease.

Authors:  Jonathan M Lee; Shoukat Dedhar; Raghu Kalluri; Erik W Thompson
Journal:  J Cell Biol       Date:  2006-03-27       Impact factor: 10.539

10.  Role of response gene to complement 32 in diseases.

Authors:  Sonia I Vlaicu; Cornelia Cudrici; Takahiro Ito; Matthew Fosbrink; Cosmin A Tegla; Violeta Rus; Petru A Mircea; Horea Rus
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-03-31       Impact factor: 4.291

View more
  13 in total

1.  Regulator of Cell Cycle Protein (RGCC/RGC-32) Protects against Pulmonary Fibrosis.

Authors:  Irina G Luzina; Violeta Rus; Virginia Lockatell; Jean-Paul Courneya; Brian S Hampton; Rita Fishelevich; Alexander V Misharin; Nevins W Todd; Tudor C Badea; Horea Rus; Sergei P Atamas
Journal:  Am J Respir Cell Mol Biol       Date:  2022-02       Impact factor: 7.748

Review 2.  Genetics of breast cancer bone metastasis: a sequential multistep pattern.

Authors:  Hassan Fazilaty; Parvin Mehdipour
Journal:  Clin Exp Metastasis       Date:  2014-02-04       Impact factor: 5.150

3.  Knockdown of response gene to complement 32 (RGC32) induces apoptosis and inhibits cell growth, migration, and invasion in human lung cancer cells.

Authors:  Ran Xu; Chao Shang; Jungang Zhao; Yun Han; Jun Liu; Kuanbing Chen; Wenjun Shi
Journal:  Mol Cell Biochem       Date:  2014-05-16       Impact factor: 3.396

4.  SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma.

Authors:  Yang Yu; Yan Chen; Jianxia Ma; Xiaofeng Yu; Guanzhen Yu; Zhaoshen Li
Journal:  Tumour Biol       Date:  2015-10-21

5.  Response gene to complement 32 suppresses adipose tissue thermogenic genes through inhibiting β3-adrenergic receptor/mTORC1 signaling.

Authors:  Sisi Chen; Xiaohan Mei; Amelia Yin; Hang Yin; Xiao-Bing Cui; Shi-You Chen
Journal:  FASEB J       Date:  2018-03-26       Impact factor: 5.191

6.  Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium.

Authors:  Charles E Birse; Robert J Lagier; William FitzHugh; Harvey I Pass; William N Rom; Eric S Edell; Aaron O Bungum; Fabien Maldonado; James R Jett; Mehdi Mesri; Erin Sult; Elizabeth Joseloff; Aiqun Li; Jenny Heidbrink; Gulshan Dhariwal; Chad Danis; Jennifer L Tomic; Robert J Bruce; Paul A Moore; Tao He; Marcia E Lewis; Steve M Ruben
Journal:  Clin Proteomics       Date:  2015-07-16       Impact factor: 3.988

7.  RGCC balances self-renewal and neuronal differentiation of neural stem cells in the developing mammalian neocortex.

Authors:  Zhenming Guo; Mengxia Chen; Yiming Chao; Chunhai Cai; Liangjie Liu; Li Zhao; Linbo Li; Qing-Ran Bai; Yanxin Xu; Weibo Niu; Lei Shi; Yan Bi; Decheng Ren; Fan Yuan; Shuyue Shi; Qian Zeng; Ke Han; Yi Shi; Shan Bian; Guang He
Journal:  EMBO Rep       Date:  2021-07-29       Impact factor: 9.071

8.  TFIIB-related factor 2 is associated with poor prognosis of nonsmall cell lung cancer patients through promoting tumor epithelial-mesenchymal transition.

Authors:  Yu Tian; Ming Lu; Weiming Yue; Lin Li; Shuhai Li; Cun Gao; Libo Si; Lei Qi; Wensi Hu; Hui Tian
Journal:  Biomed Res Int       Date:  2014-03-17       Impact factor: 3.411

9.  Prostaglandin E2 stimulates β1-integrin expression in hepatocellular carcinoma through the EP1 receptor/PKC/NF-κB pathway.

Authors:  Xiaoming Bai; Jie Wang; Yan Guo; Jinshun Pan; Qinyi Yang; Min Zhang; Hai Li; Li Zhang; Juan Ma; Feng Shi; Wei Shu; Yipin Wang; Jing Leng
Journal:  Sci Rep       Date:  2014-10-07       Impact factor: 4.379

Review 10.  [Advances in the molecular mechanisms and prognostic significance of EMT in non-small cell lung cancer].

Authors:  Qinchen Cao; Lujun Zhao; Ping Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.